Malignant Mesothelioma In Situ: Clinical and Pathologic Implications
Authors:
- 1 June 2020
- journal article
- editorial
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 15 (6) , 899-901
Abstract
No abstract availableFunding Information
- University of British Columbia
This publication has 12 references indexed in Scilit:
- Update on the management of malignant peritoneal mesotheliomaTranslational Lung Cancer Research, 2018
- Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant MesotheliomasArchives of Pathology & Laboratory Medicine, 2018
- What is the significance of non‐specific pleuritis? A trick questionThe Clinical Respiratory Journal, 2018
- Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysisOncotarget, 2017
- Long-term outcome of patients with nonspecific pleurisy at medical thoracoscopyRespiratory Medicine, 2017
- The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesotheliomaLaboratory Investigation, 2016
- Clinical Investigation of Benign Asbestos Pleural EffusionPulmonary Medicine, 2015
- New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?Archives of Pathology & Laboratory Medicine, 2015
- Surgical Management of Malignant Pleural MesotheliomaThoracic Surgery Clinics, 2013